WallStSmart

Boston Scientific Corp (BSX)vsSS Innovations International Inc. Common Stock (SSII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 55558% more annual revenue ($20.07B vs $36.07M). BSX leads profitability with a 14.4% profit margin vs -32.1%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

SSII

Avoid

22

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -0.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for SSII.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

SSII1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
192.5%10/10

Revenue surging 192.5% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

SSII4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.07B3/10

Smaller company, higher risk/reward

Price/BookValuation
23.1x2/10

Trading at 23.1x book value

Return on EquityProfitability
-43.4%2/10

ROE of -43.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : SSII

The strongest argument for SSII centers on Revenue Growth. Revenue growth of 192.5% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : SSII

The primary concerns for SSII are EPS Growth, Market Cap, Price/Book.

Key Dynamics to Monitor

BSX profiles as a growth stock while SSII is a hypergrowth play — different risk/reward profiles.

SSII carries more volatility with a beta of 1.48 — expect wider price swings.

SSII is growing revenue faster at 192.5% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 22/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

SS Innovations International Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

SS Innovations International, Inc., is a commercial-stage surgical robotics company in India and internationally. The company is headquartered in Gurugram, India.

Visit Website →

Want to dig deeper into these stocks?